

MORPHOSYS AG

ISIN: DE0006632003 WKN: 663200 Asset Class: Stock

Company



2024/07/16 11:16:49

Price
67.75
EUR

Difference  0.00%(0.00)



Contact Details

MORPHOSYS AG Tel: +49-89-89927-0
-- Fax: +49-89-89927-222
Semmelweisstrasse 7 Web: <http://www.morphosys.de>
82152 Planegg E-mail: info@morphosys.com

Company Profile

MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulumimmetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|--------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 814,021,000 | | 1,089,040,000 | | 1,132,969,000 | |
| Common stock capital | | 37,655,000 | | 34,231,000 | | 34,231,000 |
| Fixed assets | 1,212,289,000 | | 1,307,891,000 | | 1,423,284,000 | |
| Equity capital of a company | | 49,049,000 | | 157,409,000 | | 244,875,000 |
| Cash and cash equivalents | 158,499,000 | | 402,350,000 | | 123,248,000 | |
| Accrued liabilities | | 28,363,000 | | 8,674,000 | | 1,576,000 |
| Other assets | - | - | - | - | - | - |
| Current liabilities | | 264,309,000 | | 278,346,000 | | 284,538,000 |
| Prepayments and accrued income | - | - | - | - | - | - |
| Non-current liabilities | | 1,712,952,000 | | 1,961,176,000 | | 2,026,839,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 1,425,221,000 | | 1,616,129,000 | | 1,681,067,000 |
| Total assets | 2,026,311,000 | 2,026,311,000 | 2,396,932,000 | 2,396,932,000 | 2,556,254,000 | 2,556,254,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|---------------------|-----------|-----------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | 564 | 647 | 732 |
| Equity ratio | 2.42% | 6.57% | 9.58% |
| Debt-equity ratio | 4,031.18% | 1,422.74% | 943.90% |

Others

| | 2023 | 2022 | 2021 |
|------------------|-------|---------|--------|
| Tax Expense Rate | 0.65% | 772.40% | 12.96% |

MORPHOSYS AG

ISIN: DE0006632003 WKN: 663200 Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|---|--------------|--------------|--------------|
| Turnover | 238,278,000 | 278,267,000 | 179,611,000 |
| Net income | -189,734,000 | -151,058,000 | -514,460,000 |
| EBIT | -107,488,845 | 133,998,322 | -525,707,538 |
| Operating income before taxes | -182,748,000 | 21,825,000 | -591,050,000 |
| Cash Flow | -279,448,000 | -366,845,000 | -484,572,000 |
| Net interest income | -75,259,000 | -112,172,000 | -65,343,000 |
| Research and development expenses | 266,646,000 | 284,543,000 | 219,072,000 |
| Income taxes | -1,188,000 | 168,578,000 | -76,590,000 |
| Result from investments in subsidiaries, associates and other | -8,174,000 | -4,305,000 | 0 |
| Revenues per employee | 422,479 | 430,088 | 245,371 |

Board of Directors

| | |
|----------------|-----------------------------|
| Heinrich Moisa | Member of Supervisory Board |
| Romain Lege | Member of Supervisory Board |
| Sharon Curran | Member of Supervisory Board |
| Silke Mainka | Member of Supervisory Board |

Members of Management Board

| | |
|--------------------|-------------------------------|
| Arkadius Pichota | Chairman of Managing Board |
| Barbara Krebs-Pohl | Member of Executive Committee |
| Tim Demuth | Member of Executive Committee |
| Charlotte Lohmann | Member of Executive Committee |
| Lukas Gilgen | Member of Executive Committee |